On November 3, Pfizer reported third-quarter adjusted earnings of $0.87 per share, above analyst estimates of $0.735 to $0.74. Sales were $16.58 billion, exceeding estimates of $15.85 billion to $15.9 billion, but down 0.4% from $16.7 billion a year earlier. The company raised its financial guidance and appointed a new CFO. Pfizer shares edged lower despite the earnings beat and guidance increase.
The pharma giant reported adjusted earnings of 87 cents per share, beating analyst estimates while announcing a leadership transition in the CFO role.
Read the full storyThe results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 18.4%; revenue above the estimate by 4.6%.